Acrometa Posts Record Revenue of S$69.5 Million for FY2023, Continues to Pursue New Opportunities in Co-Working Lab Space Business Nov 29, 2023 20:00 HKT | |
|
Nano-sized probes reveal how cellular structure responds to pressure Nov 21, 2023 07:00 HKT | |
|
Acrometa Subsidiary Signs Two MOUs to Develop Co-Working Laboratory Space Business in China Nov 17, 2023 21:00 HKT | |
|
The Largest Biotech City in Europe Will Soon Be Built, With an Investment Amounting to 7 Billion Euros Nov 17, 2023 09:30 HKT | |
|
Envision Pharma Group Announces New AI Innovation Board and Appoints Chairwoman Nov 15, 2023 20:00 HKT | |
|
ZAGENO Secures Esteemed Placement in the 2023 ProcureTech100 Elite Nov 15, 2023 20:00 HKT | |
|
Indonesia's ITS Launches 7 MedTech Devices Based on Various Integrated Technologies Nov 09, 2023 21:00 HKT | |
|
BioMed X Launches a New Call for Application in Autoimmune Disease Research Nov 07, 2023 19:00 HKT | |
|
Acrometa Group Signs MOU for Sand Concession, Opening New Business Opportunities in the Region Nov 06, 2023 21:00 HKT | |
|
DC Healthcare Unveils Innovative Skincare Range 'newB' Under Subsidiary Ten Doctors Sdn Bhd Nov 01, 2023 19:00 HKT | |
|
BioMed X and AbbVie Start New Research Project in the USA Nov 01, 2023 07:00 HKT | |
|
Acrometa to Focus on Laboratory Construction and Co-Working Laboratory Space Business Oct 31, 2023 21:00 HKT | |
|
EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine Oct 27, 2023 21:00 HKT | |
|
四环医药(0460.HK)旗下轩竹生物自主研发吡罗西尼单药II期试验入选2023 ESMO 为晚期HR+/HER2-乳腺癌患者提供了新思路 Oct 24, 2023 10:50 HKT | |
|
四環醫藥(0460.HK):旗下軒竹生物自主研發吡羅西尼單藥II期試驗入選2023 ESMO 重磅臨床試驗結果再次登上國際舞台 Oct 24, 2023 10:49 HKT | |
|
아방스 클리니컬, 45개의 한국 생명 공학 기업 초청해 한국과 호주에서 미국으로 이어지는 글로벌레디 신약 개발 경로에 대한 설명회 개최 Oct 19, 2023 18:00 HKT | |
|
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US Oct 19, 2023 09:00 HKT | |
|
四环医药(0460.HK):旗下轩竹生物自主研发治疗晚期乳腺癌新药上市申请获国家药监局受理 Oct 17, 2023 16:03 HKT | |
|
四環醫藥(0460.HK):旗下軒竹生物自主研發治療晚期乳腺癌新藥上市申請獲國家藥監局受理 Oct 17, 2023 16:02 HKT | |
|
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical: The NDA of the New Drug, independently developed for the treatment of advanced breast cancer was accepted by NMPA Oct 17, 2023 16:01 HKT | |
|